Zenlabs Ethica Ltd (BSE: 530697) is a Chandigarh-based company in the Health Care Distributors industry. With a market capitalisation of ₹18 Cr, it ranks #4,679 by market cap among the 6,137 Indian listed companies on FinBizNet, and #7 of 11 in Health Care Distributors. At ₹26.95 (as of 25 Oct 2026), the share price is 32.6% below its 52-week high of ₹39.99 and 63.3% above its 52-week low of ₹16.50. The share price is down 12.8% over one year and down 3.7% over three months.
| Current Price | ₹26.95 |
|---|---|
| Market Cap | ₹18 Cr |
| BSE Code | 530697 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors |
| P/E Ratio | -10.1 |
| Return on Equity | -20.44% |
| Return on Assets | 1.43% |
| 52-Week Range | ₹16.50 – ₹39.99 |
| 1-Year Price Change | -12.8% |
| 3-Month Price Change | -3.7% |
| Beta (1Y) | 0.79 |
| Dividend Yield | 0.00% |
| Headquarters | Chandigarh |
| Website | www.zenlabsethica.com |
Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, S
1. Trading of Pharmaceuticals Formulation-This segment engages in the trade of pharmaceutical products.
1. Pharmaceuticals Formulation-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Trimurthi Ltd | ₹181 Cr | 53.1 | 7.99% | — | +48.6% |
| Vaidya Sane Ayurved Laboratories | ₹169 Cr | — | 11.99% | — | -43.5% |
| Achyut Healthcare Ltd | ₹139 Cr | 463.1 | 0.95% | — | +15.0% |
| Balaxi Pharmaceuticals Ltd | ₹122 Cr | 85.9 | 0.59% | ₹81 Cr | -50.2% |
| Chanfta Bhagat Pharma Ltd | ₹30 Cr | 9.9 | 2.91% | — | -5.1% |
| Medico Intercontinental Ltd | ₹25 Cr | -7.8 | -27.14% | ₹14 Cr | -34.9% |
| Zenlabs Ethica Ltd | ₹18 Cr | -10.1 | -20.44% | — | -12.8% |
| Rubra Medicaments Ltd. | ₹18 Cr | 11.9 | 12.67% | — | -37.7% |
| Nexus Surgical & Medicare Ltd | ₹17 Cr | 21.7 | 51.41% | — | +76.5% |
Listed by market capitalisation. Ratios are shown for context only.
Zenlabs Ethica Ltd is trading at ₹26.95, with a market capitalisation of ₹18 Cr.
Zenlabs Ethica Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors).
Zenlabs Ethica Ltd has a P/E of -10.1 and a return on equity of -20.44%.
Zenlabs Ethica Ltd is listed on the BSE under the scrip code 530697.
Zenlabs Ethica Ltd's share price is down 12.8% over one year and down 3.7% over three months. Its 52-week range is ₹16.50 to ₹39.99.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.